Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019204 (hepatocellular carcinoma)
 71,386 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Eleven unresectable hepatoma patients and three metastatic tumor patients with colonic cancer underwent ligation and/or catheterization of the hepatic artery of the main tumor-bearing zone. Mitomycin C (liquid or microcapsulated) or Adriamycin were administered via the catheter intermittently or continuously with a portable pump device. In follow-up study the tumor size was frequently visualized by arteriography via the cannula. Some tumors became smaller with calcification. The levels of alpha-Fetoprotein of CEA in some cases dropped remarkably and stayed low for a fairly long period. There was no immediate postoperative death. Six of 11 unresectable hepatoma patients survived longer than 8 months with a maximum survival of 17.5 months. Two of three metastatic patients have survived more than 11 months at this writing. This method seems effective for prolongation of patient survival.
 ...
PMID:Ligation and catheterization of the hepatic artery for palliative treatment of malignant hepatic tumors. 619 88

Mitomycin C microcapsules (MMC-mc), which were developed as a novel drug carrier, have proved to exert a potential therapeutic effect due to both microinfarction and sustained drug action (chemo-embolization), when infused into a tumor supplying arteries. Experimental studies have demonstrated that chemo-embolization with MMC-mc produces a definitely marked and extensive cytotoxicity in target tissues as compared with traditional arterial chemotherapy, embolization or combination of both. Sixty-seven patients with advanced hepatoma were treated with intra-arterial MMC-mc during the period from 1978 to 1982. Since the majority of patients were in far advanced stages, 56 patients received only single or two infusions of an average dose of 20 mg MMC-mc. Objective tumor reduction greater than 25% in area was observed in 22 (40%) of measurable 55 tumors. Elevated serum alpha-fetoprotein in 26 patients improved in 22 (85%). Relative survival rates of 59 patients without distant metastasis were 64% at 3 months, 49% at 6 months and 26% at 12 months. Side effects such as bone marrow depression, decreased liver function, fever, anorexia, pain and infection were experienced in 9 to 39%, but the majority of them were mild and controllable. Our preliminary experience suggests that MMC-mc can be effectively used in treatment of liver tumors as a palliative but also as a preoperative measure. Further clinical trials including controlled study may well demonstrate the advantages of MMC-mc.
 ...
PMID:[Chemo-embolization with mitomycin C microcapsules for hepatoma]. 620 39

Mitomycin C (MMC) was conjugated to horse anti-rat alpha-fetoprotein (AFP) antibody at the N-1a position through a glutaric acid-derived spacer arm. In vitro studies showed that MMC was spontaneously and slowly released from the conjugate. The conjugate caused a greater inhibition of both the in vitro and in vivo tumor growth of the AFP-producing rat hepatoma AH66 than did a mixture of anti-rat AFP antibody and MMC or a similar conjugate of MMC with normal horse immunoglobulin.
 ...
PMID:Enhanced antitumor activity of mitomycin C conjugated with anti-alpha-fetoprotein antibody by a novel method of conjugation. 620 59

Cyclic adenosine 3':5'-monophosphate (cyclic AMP) levels in six lines of rat ascites hepatoma cells were determined after the treatment with isoproterenol. The maximum increase of cyclic AMP levels was induced by the treatment with 10(-7) M of isoproterenol in each cell line, though the difference was observed at the time to reach the maximum levels. Following the treatment with 10(-7) M of isoproterenol, cyclic AMP levels increased by 55 to 80% of control in AH-44, AH-130 and AH-7974 cells, by 25 to 45% in AH-41C and AH-109A cells, and slightly in AH-13 cells. The combined cytotoxic effect of isoproterenol and mitomycin C was studied using AH-13, AH-44 and AH-130 cells. The cytotoxicity of mitomycin C on AH-44 and AH-130 cells was potentiated by the pretreatment with 10(-7) M of isoproterenol that was not cytotoxic by itself, but such a potentiation was not observed in AH-13 cells. The cyclic AMP levels were examined in the cells after the combined treatment. Mitomycin C by itself hardly affected the levels in three cell lines. In AH-44 and AH-130 cells, however, the period of the high levels of cyclic AMP was longer in the combined treatment than in the treatment with isoproterenol alone. On the other hand, the cyclic AMP level in AH-13 cells was hardly affected by each agent or the combined treatment. These results suggest that the combination effect of isoproterenol and mitomycin C is closely related to the increase of cyclic AMP in the cells treated with isoproterenol.
 ...
PMID:Relationship between enhancement of cytotoxic effect of mitomycin C and increase of intracellular cyclic adenosine 3':5'-monophosphate by isoproterenol in rat ascites hepatoma cells. 630 80

Continuous hepatic arterial infusion chemotherapy (HAI) and chemoembolization by microcapsulated Mitomycin C (MMC-m. c) were performed in patients with unresectable hepatoma or metastatic tumors of the liver. MMC-m. c showed significant antitumor effect and improvement of survival rate in unresectable hepatoma and liver metastasis of the breast cancer. Especially in liver metastasis of the breast cancer, MMC-m. c gained 80% of partial response rate and 11 months in 50% survival time. HAI was effective in multiple liver metastasis of colon and stomach cancer, showing 40% of one-year survival rate. A combination chemotherapy of HAI and MMC-m. c was performed in two cases of liver metastasis of the colon cancer. Tumor response was 100% in partial response rate. One of them died at 8 months and the other is alive at 8 months now.
 ...
PMID:[Comparison between continuous arterial infusion chemotherapy and mitomycin C microcapsule administration in primary and metastatic liver cancer]. 630 62

The present paper discusses the efficacy of cancer chemotherapy in 46 patients with advanced hepatocellular carcinoma. In most of patients, Adriamycin (20-40 mg) or Mitomycin C (20 mg) was given by one shot injection via the hepatic artery and followed by serial administration of anticancer agents such as 5-fluorouracil (300-750 mg/day), Adriamycin and Toyomycin. Results were as follows: 1) The complete response was not seen. 2) The partial response (more than 50% decrease of the tumor size) was observed in 6 of 46 patients (13%) for 34 to 457 days. 3) Absence of tumor thrombi in the portal vein which was observed by hepatic angiography, CT and ultrasonography, was closely correlated in the partial response and the prolongation of survival time. 4) There were no significant differences with the therapeutic response or survival time among 3 groups (E2: tumor occupation rate (TOR) 20-40%, E3: TOR 40-60%, E4: TOR above 60%). 5) Obstinate abdominal pain and abnormal liver function remarkably were improved during the chemotherapy in 11 of 18 cases (61%), and 6 of 46 cases (13 %), respectively. 6) Major causes of death were hepatic failure (45.7%), gastrointestinal bleeding (30.4%) and intra-abdominal rupture of the tumor (14.7%). 7) As side effect, some extent of hematopoietic suppression was observed in 25% of the patients treated.
 ...
PMID:[Evaluation of chemotherapy in hepatocellular carcinoma with liver cirrhosis]. 631 13

A special cannulation system was developed in order to completely isolate the liver in an extracorporeal circuit. Isolated hyperthermic liver perfusion at 40 degrees C with an average dosage of 1000 mg 5-FU was performed in 32 patients with liver metastases (29 colorectal carcinomas, 2 carcinoids, 1 primary hepatoma). 12 patients who had an overall 45% tumor invasion of the entire liver-volume as measured in CT-scan were treated exclusively by isolated liver perfusion. In that group median survival was 8 months and death occurred in the presence of extrahepatic metastases. Better results are achieved with isolated liver perfusion followed by intraarterial short-time infusions (Mitomycin C/5-FU) via an Implantofix catheter. Median actual survival in this group is 12 months, the longest follow-up period is 23 months.
 ...
PMID:[Isolated liver perfusion in advanced metastases of colorectal cancers]. 636 2

As a preliminary study to apply thermotherapy or thermochemotherapy to the treatment of peritoneal dissemination of gastric cancer, a continuous hyperthermic peritoneal perfusion (CHPP) was carried out for the experimental peritoneal dissemination of Donryu rats inoculated with AH100B ascitic hepatoma cells (AH100B cells). Firstly, the cytotoxicity of heat on AH100B cells was studied. No cytotoxicity was observed at 37 degrees C, but mild cytotoxicity was noted at 41.5 degrees C, and marked rise in cytotoxicity was seen at 42.5 degrees C. These cytotoxicity increased with addition to Mitomycin C and prolongation of the heating time. Next, on the 1st, 5th and 10th day after inoculation of AH100B cells, the Donryu rats were treated as follows: Group 1; CHPP (37 degrees C for 1 hr), Group 2; CHPP (41.5 degrees C for 1 hr), Group 3; (42.5 degrees C for 1 hr), Group 4; CHPP (41.5 degrees C for 1 hr)+MMC 1 mg/kg (intraperitoneal administration immediately after completion of CHPP). Group 5; MMC 1 mg/kg (intraperitoneal administration). Death within 48 hours after perfusion occurred in one rat of the 41.5 degrees C perfusion group and 14 rats of the 42.5 degrees C perfusion group. Comparison of the survival time on these groups showed the most remarkable life-prolonging effect in CHPP (41.5 degrees C)+MMC group. On the basis of the results of this study, the CHPP method combined with anti-cancer chemotherapy is considered to be an useful treatment for peritoneal dissemination of cancer.
 ...
PMID:[Experimental studies on continuous hyperthermic peritoneal perfusion in the treatment for peritoneal metastases of cancer]. 642 35

Intra-arterial infusion chemotherapy was performed in 50 patients with cancer of the liver including 12 primary hepatoma and 38 metastatic cancers, at Kurashiki Central Hospital from December 1977 through December 1981. B.D. Fomocath 5 French catheter was inserted through the lateral femoral circumflex artery and advanced retrogradely to the common hepatic or proper hepatic artery using a loop catheter technique and the catheter was connected to the tube of infusion pump. The dose of 5-Fluorouracil and Mitomycin C was 250 mg per day and 4-10 mg once a week, respectively. The patients had average survival of 8.2 months in hepatoma and 4.8 months in metastatic tumor. The results were unfortunately not encouraging but this regimen occasionally provides excellent results and has no contraindication.
 ...
PMID:[Treatment of unresectable liver cancer with intrahepatic arterial infusion chemotherapy]. 682 Aug 86

The purposes of this work were twofold: firstly to determine whether intratumor chemoimmunotherapy was more effective than either treatment alone or systemic therapy and; secondly to study how the intratumor therapy affected on the development of the tumor-specific immunity. Inbred male C3H/He mice and mouse ascited hepatoma 134 (MH 134) of C3H origin were used as host-tumor system. Mitomycin C was used as the chemotherapeutic agent and BCG as the immunopotentiating agent. Intratumor treatment of MMC + BCG led to complete cure in 85 percent of the mice. The lymph node metastases were markedly inhibited in the group treated with MMC + BCG compared to the groups treated with MMC alone or BCG alone. The growth of rechallenged tumor was investigated; 79% of mice treated with MMC + BCG were immune to rechallenge, whereas 57% of mice treated with BCG alone. The number of PFC and DTH against SRBC of the mice treated with MMC intraperitoneally significantly decreased compared to that treated with MMC intratumorally.
 ...
PMID:[Experimental study on local immunochemotherapy]. 682 Aug 89


<< Previous 1 2 3 4 5 6 7 8 9 Next >>